Detailed Information

Cited 12 time in webofscience Cited 12 time in scopus
Metadata Downloads

Improvement of liver function and non-invasive fibrosis markers in hepatitis B virus-associated cirrhosis: 2years of entecavir treatment

Authors
Shin, Seung KakKim, Jeong HanPark, HyeonsuKwon, Oh SangLee, Hyun JungYeon, Jong EunByun, Kwan SooSuh, Sang JunYim, Hyung JoonKim, Yun SooKim, Ju Hyun
Issue Date
Dec-2015
Publisher
Blackwell Publishing Inc.
Keywords
entecavir; hepatitis B virus; liver fibrosis; liver function
Citation
Journal of Gastroenterology and Hepatology, v.30, no.12, pp.1775 - 1781
Indexed
SCIE
SCOPUS
Journal Title
Journal of Gastroenterology and Hepatology
Volume
30
Number
12
Start Page
1775
End Page
1781
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/7281
DOI
10.1111/jgh.13020
ISSN
0815-9319
Abstract
Background and Aim Entecavir (ETV) induces biochemical and histologic improvement of the liver in patients with chronic hepatitis B. This study aimed to confirm that 2 years of ETV treatment improves liver function and non-invasive fibrosis markers in patients with hepatitis B virus (HBV)-associated cirrhosis. Methods A total 472 naïve patients with HBV-associated cirrhosis was treated with ETV for at least 2 years, between March 2007 and December 2012. Model for end-stage liver disease and Child-Pugh (CP) score were used to evaluate the improvement of liver function. Aspartate transaminase to platelet ratio index, FIB-4 index, and fibrosis index were used to evaluate the improvement of fibrosis. Results The final 370 of 472 patients with HBV-associated cirrhosis were enrolled. Mean age was 51 ± 10 years, and 240 patients (64.9%) were men. The distribution of CP class was 71.1% in A, 24.6% in B, and 4.3% in C. Mean end-stage liver disease and CP score changed over the study period from 8.5 ± 4.6 to 6.2 ± 4.2 (P < 0.001) and from 6.2 ± 1.6 to 5.6 ± 0.9 (P < 0.001), respectively. Aspartate transaminase to platelet ratio index, FIB-4 index, and fibrosis index changed from 3.6 ± 4.5 to 1.5 ± 1.5 (P < 0.001), from 7.0 ± 6.2 to 3.9 ± 2.8 (P < 0.001), and from 3.3 ± 0.9 to 2.5 ± 1.1 (P < 0.001), respectively. Conclusions After 2 years of treatment, ETV improves liver function and non-invasive fibrosis markers in patients with HBV-associated cirrhosis.
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Gastroenterology and Hepatology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Yim, Hyung Joon photo

Yim, Hyung Joon
Ansan Hospital (Department of Gastroenterology and Hepatology, Ansan Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE